Adaptimmune creates engineered T‑cell receptor (TCR) therapies that enable patient T cells to recognize peptide‑HLA complexes derived from intracellular tumor proteins, expanding treatment options for solid‑tumor cancers. Its platform combines target discovery, affinity‑enhanced TCR design, and a pre‑clinical safety screen to produce high‑potency, highly specific candidates for oncology developers and clinicians.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HCFounders
Product
Problem
Cancer patients, especially those with solid tumors, often have limited treatment options because existing immunotherapies struggle to recognize cancer-specific peptides and may cause off‑target effects.
Solution
Adaptimmune develops engineered T‑cell receptor (TCR) therapies that enhance the natural immune response to cancer. By affinity‑optimizing the variable regions of TCR α and β chains, the platform creates receptors that can bind peptide‑HLA complexes derived from intracellular tumor proteins, expanding the range of targetable antigens beyond surface markers. A comprehensive pre‑clinical safety screen minimizes cross‑reactivity with healthy tissue, improving specificity. The technology platform integrates target identification, TCR engineering, and rigorous screening to advance candidates toward clinical trials for multiple solid‑tumor indications.
Target Audience
Primary customers are oncology pharmaceutical developers and clinical researchers seeking TCR‑based therapies for solid‑tumor indications, as well as healthcare providers treating patients with cancers that have limited existing options.
Features
- Affinity‑enhanced TCRs that recognize peptide‑HLA complexes from intracellular cancer proteins
- Ability to target a broad spectrum of antigens, increasing therapeutic options for solid tumors
- Proprietary pre‑clinical safety package to reduce off‑target binding and cross‑reactivity
- Integrated platform for target discovery, TCR engineering, and selection of high‑potency candidates
- Large pipeline of validated tumor-associated targets supporting multiple clinical programs
- Engineered TCRs are introduced into patient T cells, leveraging the body’s natural immune system for tumor eradication